Safety and Efficacy Study of PI3K Delta Inhibitor in Autoimmune Hemolytic Anemia Patients Who Failed Two-round Therapy

Conditions:   Autoimmune Hemolytic Anemia;   Failure of Two Rounds of Treatment Intervention:   Drug: Linperlisib Sponsors:   Institute of Hematology & Blood Diseases Hospital;   YL-Pharma Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials